Ovid, Angelini sign Europe licensing deal worth up to $232.5M for rare disease drug

In exchange for a $20 million upfront payment and up to $212.5 million in milestones, Italy-based Angelini will gain exclusive development, manufacturing and commercialzation rights in Europe for OV101, a drug for Angelman syndrome.